Skip to content
    Kinnevik logo

    Kinnevik

    Stockholm, SwedenFounded 1936

    Kinnevik is a leading growth investor and active owner providing patient capital to challenger technology-enabled businesses in Europe and the US. Founded in 1936 and listed on Nasdaq Stockholm, it focuses on healthcare, software, and climate tech, partnering with companies from early-stage to growth-phase.

    Deal activity decreased year-over-year (6 deals in the last 12 months vs 9 prior). Average disclosed round size is $101.7M (across 101 rounds with reported amounts).

    Find people at Kinnevik on Goldilocks AI

    Portfolio

    81

    Fund Size

    —

    Top Stage

    Series C

    Last 12 Mo

    6

    Team

    Charlie Malmquist

    Charlie Malmquist

    Director of Corporate Communications

    Anders Strandberg

    Anders Strandberg

    Legal

    Axel Eklund Bona

    Axel Eklund Bona

    Finance

    Linda Andersson

    Linda Andersson

    Finance

    Sophia Uddén

    Sophia Uddén

    Finance

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    131 investments
    CompanyRoundAmountDate
    Anterior logoAnteriorSeries B$40MFeb 2026
    Mews logoMewsSeries D—Jan 2026
    Oviva logoOvivaSeries D—Jan 2026
    Tandem Health logoTandem HealthSeries B$100MJan 2026
    EEncubeUnknown$23MOct 2025
    BIMA logoBIMAPre-Seed—Oct 2025
    Nory logoNorySeries B$37MSep 2025
    Strand Therapeutics logoStrand TherapeuticsGrowth—Aug 2025
    Tandem Health logoTandem HealthSeries A—Jun 2025
    BBreathe Battery TechnologiesSeries B$21MMay 2025
    Jobandtalent logoJobandtalentSeries F$103MApr 2025
    JJob&TalentSeries F—Apr 2025
    Mews logoMewsSeries C$75MMar 2025
    TravelPerk logoTravelPerkSeries E—Jan 2025
    Mews logoMewsGrowth—Jan 2025
    Enveda Biosciences logoEnveda BiosciencesSeries D$150MJan 2025
    Perk logoPerkSeries E$200MJan 2025
    Mews logoMewsSeries A$7MJan 2025
    HungryPanda logoHungryPandaUnknown$55MSep 2024
    Mews logoMewsGrowth$100MSep 2024
    SpringHealth logoSpringHealthSeries E$100MJul 2024
    bunch logobunchSeries A$35MJul 2024
    Enveda Biosciences logoEnveda BiosciencesSeries B$55MJun 2024
    Nory logoNorySeries A—May 2024
    Transcarent logoTranscarentSeries D$126MMay 2024
    Page 1 of 6

    Top Co-Investors

    Last updated: 7 October 2026